Skip to search formSkip to main contentSkip to account menu

GTx-758

Known as: Estrogen Receptor Agonist GTx-758 
An orally available, nonsteroidal selective estrogen receptor (ER) alpha agonist with potential antineoplastic activity. Upon administration of GTx… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PD32-04 PHASE I/II CLINICAL TRIAL TO ASSESS SAFETY AND EFFICACY OF INTRATUMORAL AND SUBCUTANEOUS INJECTION OF HVJ-E TO CASTRATION RESISTANT PROSTATE CANCER PATIENTS
2015
2015
Effect of the ERα agonist, GTx-758 (250 mg daily), on total and free testosterone, and PSA, in men with castration resistant prostate cancer (CRPC) maintained on LHRH therapy.
e16020 Background: LHRH agents used for androgen deprivation therapy (ADT) were intended to lower total testosterone (T) levels… 
2015
2015
Evaluation of the ER{alpha} agonist, GTx-758 (250 mg daily), in men with metastatic (mCRPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC).
201 Background: LHRH agents used for androgen deprivation therapy (ADT) were intended to lower total testosterone (T) levels to… 
2014
2014
The effect of low-dose GTx-758 on free testerone levels in men with metastatic castration resistant prostate cancer (mCRPC).
60 Background: Luteinizing hormone-releasing hormone (LHRH) agents used for androgen deprivation therapy (ADT) were designed to… 
2014
2014
Prostate cancer: GTx-758 reduces testosterone
2013
2013
Effect of GTx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer.
104 Background: Androgen deprivation therapy (ADT) improves disease-free survival in men with advanced prostate cancer, but… 
2013
2013
The free hormone hypothesis: Correlation of decreases in PSA with free testosterone rather than total testosterone in men with advanced prostate cancer treated with GTx-758.
e16015 Background: Androgen deprivation therapy (ADT) improves disease-free survival but disease progression is related, in part… 
2013
2013
Rate of hot flashes in patients with advanced prostate cancer treated with GTx-758.
129 Background: When androgen deprivation therapy (ADT) for prostate cancer was first developed, life expectancy for men with… 
2013
2013
Serum IGF-1 levels in men with advanced prostate cancer treated with the ERα agonist, GTx-758.
171 Background: The insulin pathway and, in particular, insulin-like growth factor-1 (IGF-1), has been implicated in the… 
2013
2013
Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer.
222 Background: Men with advanced prostate cancer are being treated with androgen deprivation therapy (ADT) for longer periods of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)